153 related articles for article (PubMed ID: 17204206)
1. [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
Lu PP; Meng ZY; Zhou MX; Wang MW; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1258-61. PubMed ID: 17204206
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
4. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
Cancer Immunol Immunother; 2009 Oct; 58(10):1715-22. PubMed ID: 19294384
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
6. CD22 as a target of passive immunotherapy.
Cesano A; Gayko U
Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
[TBL] [Abstract][Full Text] [Related]
7. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
8. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
9. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
O'Donnell RT; Ma Y; McKnight HC; Pearson D; Tuscano JM
Cancer Immunol Immunother; 2009 Dec; 58(12):2051-8. PubMed ID: 19437017
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
Leonard JP; Goldenberg DM
Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
Kong Y; Barisone GA; Abuhay M; O'Donnell RT; Buksh Z; Yousefian F; Tuscano JM
Leuk Res; 2014 Nov; 38(11):1320-6. PubMed ID: 25241275
[TBL] [Abstract][Full Text] [Related]
12. B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.
Goldenberg DM; Stein R; Leonard JP; Steinfeld SD; Dörner T; Burmester GR
Arthritis Rheum; 2006 Jul; 54(7):2344; author reply 2344-5. PubMed ID: 16802381
[No Abstract] [Full Text] [Related]
13. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Leonard JP; Link BK
Semin Oncol; 2002 Feb; 29(1 Suppl 2):81-6. PubMed ID: 11842393
[TBL] [Abstract][Full Text] [Related]
14. CD22-directed monoclonal antibody therapy for lymphoma.
Siegel AB; Goldenberg DM; Cesano A; Coleman M; Leonard JP
Semin Oncol; 2003 Aug; 30(4):457-64. PubMed ID: 12939714
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of fully human anti-CD22 monoclonal antibodies.
Xiao X; Ho M; Zhu Z; Pastan I; Dimitrov DS
MAbs; 2009; 1(3):297-303. PubMed ID: 20065646
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
18. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
20. Epratuzumab: targeting B-cell malignancies through CD22.
Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]